Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance of Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir in Virologically Suppressed HIV-infected Adults

NCT03727152 is registered in ClinicalTrials.gov with The HIV Netherlands Australia Thailand Research Collaboration as lead sponsor.

NCT NCT03727152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03727152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance of Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir in Virologically Suppressed HIV-infected Adults
Lead sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2019
Completion date
April 4, 2023
Enrollment
170 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv